1. McKenzie CV et al. Splenomegaly: Pathophysiological bases and therapeutic options. Int J Biochem Cell Biol 2018; 94: 40-3.
2. Ishibashi H et al. Sonographic assessment and grading of spleen size. J Clin Ultrasound 1991; 19: 21-5.
3. Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol 2005; 5: 606-16.
4. Chow KU et al. Spleen size is significantly influenced by body height and sex: Establishment of normal values for spleen size at US with a cohort of 1200 healthy individuals. Radiology 2016; 279: 306-13.
5. Maymon R et al. Normal sonographic values of maternal spleen size throughout pregnancy. Ultrasound Med Biol 2006; 32: 1827-31.
6. Platzbecker U et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001; 41: 184-9.
7. Mesa RA et al. The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009; 33: 1199-203.
8. Pozo AL et al. Splenomegaly: Investigation, diagnosis and management. Blood Rev 2009; 23: 105-11.
9. Parker C et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106: 3699-709.
10. Anderson S. Newborn screening for lysosomal storage disorders. J Pediatr Health Care 2018; 32: 285-94.
11. Harrison CN, McLornan DP. Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond. Hematology Am Soc Hematol Educ Program 2017; 2017: 489-97.
12. Bonnet S et al. Indications and outcome of splenectomy in hematologic disease. J Visc Surg 2017; 154: 421-9.
13. Zaorsky NG et al. Splenic irradiation for splenomegaly: A systematic review. Cancer Treat Rev 2017; 53: 47-52.